GlassScriptPhysician profile
Adam Wesley Coe
NPI 1023338456
$7,276.62
in general payments reported to CMS, 2019-2025
33 companies · $2,090 in 2025
The $2,090 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $999 · 2020: $363 · 2021: $573 · 2022: $983 · 2023: $996 · 2024: $1,272 · 2025: $2,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,358.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,037.45 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,512.53 | 2019-2025 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $664.88 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $482.91 | 2019-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $352.30 | 2022-2025 | Ibsrela |
| Celgene Corporation | $266.65 | 2022-2023 | Zeposia |
| Aimmune Therapeutics, INC. | $204.60 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $192.51 | 2024-2025 | Vegzelma |
| Gilead Sciences, INC. | $187.90 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $156.24 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $130.95 | 2019-2024 | Ocaliva |
| Pfizer INC. | $127.14 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $125.09 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $116.05 | 2020-2024 | |
| Braintree Laboratories, INC. | $96.71 | 2019-2025 | Suflave, Sutab |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $88.77 | 2019-2025 | |
| Daiichi Sankyo INC. | $75.43 | 2024-2025 | Injectafer |
| Lilly USA, LLC | $58.10 | 2024-2025 | Omvoh |
| Novo Nordisk INC | $58.05 | 2025 | Wegovy |
| Genzyme Corporation | $55.77 | 2022-2025 | |
| Madrigal Pharmaceuticals | $49.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $37.09 | 2023-2024 | Dupixent |
| Boston Scientific Corporation | $31.73 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $24.71 | 2025 | Iqirvo |
| Medline Industries LP | $23.13 | 2025 | |
| Qol Medical, LLC | $22.25 | 2025 | Sucraid |
| Exact Sciences Corporation | $19.53 | 2025 | The Cologuard Plus Collection Kit |
| Redhill Biopharma INC. | $16.48 | 2021 | |
| Capsovision, INC. | $15.75 | 2025 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $14.58 | 2020 | |
| Allergan, INC. | $14.53 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.10 | 2021 | |
| Romark Laboratories, Lc | $5.95 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Coe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.